Thursday, 29 October 2026 Every NSE & BSE announcement, by company
ALFA Filings Every announcement, straight from the exchange
Business Update

Biocon Business Update

Biocon announced the publication of Phase III clinical data supporting the effectiveness of its biosimilar Yesafili™. The data reinforces clinical equivalence ahead of its US launch.

Source

BSE filing, NSE: BIOCON. Summary written from the filing by ALFA Finder's alert engine.

Read the filing ↗

Biocon Ltd: key numbers

Share price
₹350.70
Market cap
₹57,153 Cr
Revenue (annual)
₹16,927 Cr
Net profit (annual)
₹385.6 Cr
P/E (TTM)
115.4×Sector 46.1×
Promoter holding
44.68%+0.00% QoQ
FII holding
8.64%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

More from Biocon Ltd

All →
08:25 IST BSE
Partnership

Biocon Partnership

Biocon entered a global patent settlement and license agreement with Genentech, securing early launch dates for its biosimilar Pebrilzo® (bPertuzumab) across key global markets.

From
Genentech

Other business update announcements

All →